Oncolytic Virotherapy Market - 2024-2031

March 2024 | 47 pages | ID: O6DC28AC7048EN
DataM Intelligence

US$ 3,400.00 US$ 4,350.00 -22 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Oncolytic Virotherapy Marketis is growing with a CAGR of 23.07% during the forecast period 2026-2035.

The Oncolytic Virotherapy Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Oncolytic Virotherapy Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Therapy Type
  • Adenoviruses-based Oncolytic Viruses*
  • HSV-based Oncolytic Viruses
  • Others
By Application
  • Severe Atrophy of Maxillary Bone*
  • Melanoma
  • Prostate Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Others
Regional Analysis for Oncolytic Virotherapy Market:
  • North America (U.S., Canada, Mexico)
  • Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
  • Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
  • South America (Colombia, Brazil, Argentina, Rest of South America)
  • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
This Report Covers:
  • Go-to-market Strategy.
  • Neutral perspective on the market performance.
  • Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
  • Customized regional/country reports as per request and country level analysis.
  • Potential & niche segments and regions exhibiting promising growth covered.
  • Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Research Process:

Both primary and secondary data sources have been used in the global Oncolytic Virotherapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Market Snippet by Therapy Types
3.2. Market Snippet by Application
3.3. Market Snippet by Region

4. MARKET DYNAMICS

4.1. Market Impacting Factors
  4.1.1. Drivers:
  4.1.2. Rising research and development in cancer treatment
4.2. Restraints:
  4.2.1. Few side effects associated with the oncolytic virus
4.3. Opportunity
4.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. PEST Analysis

6. COVID-19 ANALYSIS

6.1. Analysis of Covid-19 on the Market
  6.1.1. Before COVID-19 Market Scenario
  6.1.2. Present COVID-19 Market Scenario
  6.1.3. After COVID-19 or a Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. BY THERAPY TYPE

7.1. Introduction
  7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  7.1.2. Market Attractiveness Index, By Therapy Type
7.2. Adenoviruses-based Oncolytic Viruses*
  7.2.1. Introduction
  7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. HSV-based Oncolytic Viruses
7.4. Others

8. BY APPLICATION

8.1. Introduction
  8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  8.1.2. Market Attractiveness Index, By Application
8.2. Severe Atrophy of Maxillary Bone*
  8.2.1. Introduction
  8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Melanoma
8.4. Prostate Cancer
8.5. Breast Cancer
8.6. Ovarian Cancer
8.7. Lung Cancer
8.8. Others

9. BY REGION

9.1. Introduction
  9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  9.1.2. Market Attractiveness Index, By Region
9.2. North America
  9.2.1. Introduction
  9.2.2. Key Region-Specific Dynamics
  9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    9.2.5.1. The U.S.
    9.2.5.2. Canada
    9.2.5.3. Mexico
9.3. Europe
  9.3.1. Introduction
  9.3.2. Key Region-Specific Dynamics
  9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    9.3.5.1. Germany
    9.3.5.2. The U.K.
    9.3.5.3. France
    9.3.5.4. Italy
    9.3.5.5. Spain
    9.3.5.6. Rest of Europe
9.4. South America
  9.4.1. Introduction
  9.4.2. Key Region-Specific Dynamics
  9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    9.4.5.1. Brazil
    9.4.5.2. Argentina
    9.4.5.3. Rest of South America
9.5. Asia Pacific
  9.5.1. Introduction
  9.5.2. Key Region-Specific Dynamics
  9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    9.5.5.1. China
    9.5.5.2. India
    9.5.5.3. Japan
    9.5.5.4. Australia
    9.5.5.5. Rest of Asia Pacific
9.6. Middle East and Africa
  9.6.1. Introduction
  9.6.2. Key Region-Specific Dynamics
  9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10. COMPETITIVE LANDSCAPE

10.1. Competitive Scenario
10.2. Key Developments and Strategies
10.3. Company Share Analysis
10.4. Product Benchmarking
10.5. Key Companies to Watch
10.6. Company with disruptive technology

11. COMPANY PROFILES

11.1. Amgen Inc*
  11.1.1. Company Overview
  11.1.2. Product Portfolio and Description
  11.1.3. Key Highlights
  11.1.4. Financial Overview
11.2. AstraZeneca
11.3. Shanghai Sunway Biotech Co., Ltd
11.4. TILT Biotherapeutics Ltd
11.5. Oncorus, Inc
11.6. Takara Bio Inc
11.7. Vyriad
11.8. Transgene SA
11.9. Lokon Pharma AB
11.10. Pfizer Inc
11.11. Roche(*LIST NOT EXHAUSTIVE)

12. DATAM INTELLIGENCE

12.1. Appendix
12.2. About Us and Services
12.3. Contact Us


More Publications